Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection
The Journal Of Infectious DiseasesPeer ReviewedKelly E. Dooley +112014Journals
Pregnancy and tuberculosis treatment or prophylaxis can affect efavirenz pharmacokinetics, maternal human immunodeficiency virus type 1 (HIV-1) treatment outcomes, and mother-to-child transmission (MTCT) risk.
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support